Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 12

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 12
---
           - |   |
| Series A convertible preferred stock, $0.0001 par value; 12,580 shares authorized; 1,429 and 1,894 issued and outstanding at June 30, 2025 and December 31, 2024, respectively; liquidation preference of $1,429,000 at June 30, 2025 |     |             |   1,287,315 |   |     |              |   1,708,396 |   |
| Series B convertible preferred stock, $0.0001 par value; 626 shares authorized; 0 and 273 issued and outstanding at June 30, 2025 and December 31, 2024, respectively; No liquidation preference at June 30, 2025                     |     |             |           - |   |     |              |     218,051 |   |
| Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 1,194,802 and 120,794 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively                                                    |     |             |         119 |   |     |              |          12 |   |
| Additional paid-in capital                                                                                                                                                                                                            |     |             |  71,311,399 |   |     |              |  67,142,276 |   |
| Stock subscription receivable                                                                                                                                                                                                         |     |             |     (78,750 | ) |     |              |  (1,295,444 | ) |
| Accumulated deficit                                                                                                                                                                                                                   |     |             | (81,441,099 | ) |     |              | (70,917,853 | ) |
| Total stockholders’ deficit                                                                                                                                                                                                           |     |             |  (1,633,901 | ) |     |              |  (1,894,563 | ) |
| Total liabilities and stockholders’ deficit                                                                                                                                                                                           |     | $           |   6,202,322 |   |     | $            |   6,206,929 |   |

<div align='center'>See accompanying notes to the condensed consolidated financial statements

Reflects a 1-for-100 reverse stock split effective January 8, 2025 and 1-for-20 reverse stock split effective June 13, 2025

1

CERO THERAPEUTICS HOLDINGS